Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
November 3, 2021
Earnings Call Speaker Segments
Jee Hamlyn-Harris
executiveThanks, operator, and I appreciate everyone being here today as we go over Penumbra's results for Q3 2021. You can find the press release along with the financial tables — including a reconciliation from GAAP to non-GAAP — on the Investors section of our site, www.penumbrainc.com. On this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality compliance, and business trends. Because of various risks and uncertainties — among them those we laid out in our 10-K for the year ended December 31, 2020, filed with the SEC — actual results might differ materially from what those statements state or imply. So we urge you not to place undue reliance on them, and we encourage you to look at our periodic SEC filings, including that 10-K, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock, such as, but not limited to, how the COVID-19 pandemic impacts our business, results of operations, and financial conditions. Penumbra accepts no obligation to update or revise these forward-looking statements because of new information, future events, developments, or anything else; some financial measures on this call are given on a non-GAAP basis. You'll find a reconciliation between GAAP and non-GAAP financial measures in the press release we posted. We expect the prepared remarks today to take roughly 18 minutes. Adam Elsesser, our Chairman and CEO, will give a business update. Then Maggie Yuen, our Chief Financial Officer, will go over our financial results for the third quarter. And Jason Mills, our Executive Vice President of Strategy, will talk about our updated 2021 guidance. With that, I'll hand the call over to Adam Elsesser.
Adam Elsesser
executiveThank you, Jee. Good afternoon, everyone. I appreciate you being on Penumbra's call for the third quarter of 2021. Revenue across all operations in the second quarter came to $190.1 million, which represents a rise of 25.8% versus a year earlier as reported, and 25.6% on a constant currency basis, plus a 3.2% gain over the preceding quarter; during 2021's third quarter, operating income reached $8.8 million, equal to 4.6% of revenue, versus an operating loss of $20.2 million, or 13.3% of revenue, in the comparable period a year ago. With the Delta variant spreading, especially early in the quarter, our team performed extremely well. Our Vascular division delivered record results, and Neuro had a quarter that was just shy of a record as well. Within the U.S., performance was remarkably robust, as our latest offerings in both vascular and neurothrombectomy gained significant traction. Overall, momentum built throughout the quarter, driven by the RED lineup of stroke catheters along with sustained strength in vascular thrombectomy, and embolization also performed well, especially as autumn progressed. I want to acknowledge our physician partners and hospital teams as well, who encountered challenging conditions, particularly with COVID, and put in tremendous effort looking after their patients. From our standpoint as a company, we've never been in a stronger spot to serve a greater number of patients than we are right now. As we move forward and the pandemic recedes, the three core forces that have always characterized Penumbra — ongoing innovation, recruiting top talent, and getting things done — again influenced how we worked during the third quarter, and they leave us deeply confident in our ability to deliver robust, lasting expansion over the coming years. Regarding bringing on the finest people, we continue to welcome exceptional individuals into the Penumbra family. In addition to the fresh engineers, additional experts, and elite sales professionals we've onboarded, I'd like to call attention to a few of our newly hired senior leaders. We've just added Fred Hubbard and Joan Kristensen to the team, and between them they bring many decades of high-level experience in medical devices. Fred takes the role of Senior Vice President and will lead International Commercial, with his focus set on markets outside Europe and North America. Joan joins as Vice President and Head of Europe, and she'll steer our work throughout Europe and the Middle East. On top of that, Riley Russell has joined us as Executive Vice President of third-party partnerships for Immersive Healthcare; he was previously a senior executive at Sony Interactive Entertainment, where his work involved Sony PlayStation and third-party developers. And Amir Rubin, who used to be CEO of Sixense, now leads our research in Immersive Healthcare as Executive Vice President of Research for Immersive Healthcare. Also, we'll continue to prioritize internal promotions while adding more experienced leaders to our group during the upcoming quarters. Now let's move on to discuss what we offer. Starting with the Vascular division; during Q3, we achieved a 40.3% increase compared to the same period last year, reaching $105.5 million. Within the United States, revenue from our vascular thrombectomy offerings grew by 10% over the previous quarter, fueled by strong performance across venous, PE, arterial and coronary segments; throughout Q3, we continue to see faster growth among new physician clients adopting our thrombectomy solutions, which we interpret as evidence of excellent patient results and the beneficial value that our exclusive computer-aided Lightning thrombectomy system provides to the health care system. Going forward, we are concentrating on the chance to extend the single-session therapy paradigm to far more patients. As our solid third-quarter results show, our computer-aided Lightning technology is connecting with a growing number of physicians and is turning into a core element of treatment algorithms for PE, venous and arterial procedures. In fact, Lightning 12 and Lightning 7 both delivered robust growth during the quarter, each up double digits from the prior quarter in the U.S. As with other distinctive and transformational products we have created, our Lightning platform results from our emphasis on relentless innovation devoted to what genuinely matters for successful and safe patient outcomes, and from the most gifted group of engineers and product development professionals anywhere in the industry. Beyond that, we keep putting money into innovation, clinical studies and market development efforts so we can reach the 90% of patients who can still benefit from this technology annually. All told, we have only just begun, and our team's efforts carry on. Turning to coronary, we saw a rising number of physicians using CAT RX for their patients during the quarter. CAT RX presents a massive opportunity for us, because we've only managed to reach about 10% of the coronary patients we think stand to benefit the most—namely those carrying a high thrombus burden. Beyond that, we're looking forward to CHEETAH study data being presented, which is set to take the spotlight during the clinical research session at the upcoming TCT Conference in Orlando, Florida, happening in just 2 days, on Friday, November 5. I intend to attend, and I'm hoping plenty of you will be there with us. Turning to our vascular embolization business, we matched our record results for a second quarter, despite the fact that Q2 benefited from procedures that had been deferred and were later caught up on, whereas this quarter ran into a mild COVID-related headwind. Physicians keep gravitating toward our vascular embolization lineup because of how unique and wide-ranging it is, and they're discovering additional applications for our offerings in both long-term and urgent care situations. Ruby LP in particular saw continued powerful adoption, delivering another quarter that set a record. Turning now to Neuro, third-quarter revenue there climbed 11.5% compared with the same period last year, reaching $84.7 million. All through the pandemic, our Neuro group has accomplished extraordinary things alongside the doctors we serve. The U.S. debut of RED 72 and RED 68 during the quarter could hardly have gone better. Alongside RED 62, the RED family strengthens our stroke offerings in America, which notched a strong 17% increase sequentially this quarter. Physicians in the United States have reacted very favorably to the RED series. The RED series offers tracking and clot removal abilities that are truly remarkable, powered by our new RED-glide coating technology along with proprietary catheter architecture, and these are unmatched in the field. Plus, because the RED series is so broad, physicians can pick whichever catheter fits best with the size of the patient's vessel. All in all, the RED series was built so that physicians have the technology required to use aspiration as a frontline treatment and to maximize the chances of achieving first pass success. One thing that really defines our Neuro business is how broad the portfolio is — stroke access and embolization complement each other extremely well. Our neuro access business delivered yet another record quarter, driven by continued uptake of BMX96 along with strong growth internationally. Meanwhile, our neuro embolization business nearly equaled its record Q2 performance, even with the COVID-related pressures that weighed on procedures of this type in the third quarter. Taking it all together, we expect that momentum to continue in Neuro as we keep putting investment into our team, our innovation engine and the key initiatives designed to bring our neuro products to more patients in the future. Now let me turn to our Immersive Healthcare business. During the final part of September, we held an Investor Day, and for Penumbra that represented a really significant milestone. We used that occasion to reveal that Sixense — a virtual reality technology frontrunner and someone we've worked alongside for many years — would be joining us through an acquisition, and we also shared our blueprint for creating a platform capable of bringing Immersive therapy to tens of millions of patients spanning a broad variety of health care settings. Our own hardware, our tracking technology, our software, plus distinctive content drawn from three sources — our internal studio, second-party partners, and a strong collection of third-party developers — all of that together is what constitutes the REAL platform and the ecosystem we plan to construct while striving to serve more than 50 million patients within the U.S. by itself. The response from health care professionals following this event has been overwhelmingly favorable. We remain dedicated to the significant work that lies before us. Turning now to our business outside the United States: China continues to drive substantial results for us, and we anticipate considerable chances to expand further for many years ahead. In addition, momentum remains solid in Japan, where we are eager to bring our newest stroke in neuro offerings, our full vascular product lineup and, in time, our Immersive Healthcare platform to the market. Each of our businesses in EMEA, Latin America, and Asia Pacific delivered strong year-over-year growth, and looking ahead, we see plenty of room to grow our footprint in every one of those regions. On the whole, even with the difficulties every company is up against, we have confidence that we're positioned to reach a growing number of patients through both our current and upcoming products, spanning every product category and geography we serve. At this point, I'll hand things over to Maggie, who will walk through the financial results for the quarter.
Maggie Yuen
executiveThanks, Adam. I'll go over our Q3 2021 financials now. You'll find more information in our Form 10-Q quarterly reports; for the quarter that closed on September 30, 2021, we brought in total revenues of $190.1 million, which was up 25.8% as reported and 25.6% on a constant currency basis versus Q3 2020, and 3.2% higher sequentially than Q2 2021. Sales split geographically this quarter at 70.9% U.S. and 29.1% international. Compared with the same period in 2020, reported growth for the U.S. was 23% and for international was 33.5%. Now for revenue by franchise. Our Vascular business generated $105.5 million in Q3 2021, up 40.3% reported in constant currency versus the same period a year earlier. Versus the prior quarter, Vascular revenue rose 4.7%, powered by strong U.S. peripheral thrombectomy volume performance. Our Neuro business brought in $84.7 million in Q3 2021, up 11.5% reported and 11.1% in constant currency versus the same period last year, with gains across neuro access, embolization and thrombectomy franchises. Gross margin for Q3 came in at 63.1% versus 60.2% in last year's same quarter, thanks to benefits from additional volume and a stable product mix. We're happy with how we've been able to boost manufacturing capacity and grow our supply chain and manufacturing footprint during 2021 to meet fast-rising demand for our new product launches. Over the next few months, we'll keep accelerating investment at our Roseville manufacturing site, which includes hiring and training product builders, moving multiple key manufacturing processes and enhancing efficiency and productivity. This could keep affecting margins short term, just as it did in Q3, but it will position us for strong margin expansion opportunities in the years ahead. Operating expense totaled $111.1 million for the quarter, or 59% of revenue, versus $111.1 million, or 74% of revenue, in last year's same quarter. Our R&D expenses for Q3 2021 came to $16.7 million versus $34.9 million for Q3 2020. SG&A expenses for Q3 2021 were $94.4 million versus $76.2 million for Q3 2020. During Q4 2021, we expect payments tied to research and development milestones and onetime expenses related to the Sixense acquisition. We estimate these extra expenses in Q4 2021 will fall in the range of $35 million to $45 million, mostly noncash; for Q3 2021, we posted operating income of $8.8 million, or 4.6% of revenue, versus an operating loss of $20.2 million, or 13.3% of revenue, in last year's same period; we closed Q3 with cash, cash equivalents and marketable security balance of $267 million, an increase of $28 million in operating cash. Now I'd like to hand the call to Jason to go over our 2021 guidance.
Jason Mills
executiveThanks, Maggie. Now that we've shared our third-quarter results, we're officially raising the revenue guidance range for 2021 to $735 million to $740 million, which would mean growth of 31% to 32% compared with 2020 revenue of $560.4 million. This revised guidance is up against our earlier 2021 range of $720 million to $730 million, which we provided during our second-quarter call in August. Looking ahead, we see several growth drivers, both near term and long term. For the fourth quarter, we anticipate sequential growth relative to our record third-quarter results, led mainly by vascular thrombectomy across venous, PE, arterial and coronary, continued expansion of our peripheral embolization business and a growing contribution from our new RED series of catheters for stroke intervention. As with how we've set guidance before, our updated 2021 revenue guidance reflects our present views on our markets, the timing of new product launches and other relevant inputs. I'll now hand the call back to Adam for closing remarks.
Adam Elsesser
executiveThanks, Jason, Maggie, and Jee. As we share our results for the third quarter and continue into the fourth, Penumbra is in a strong spot to serve a growing number of individuals in the coming months and years. We're putting money into ongoing innovation across Neuro and Vascular, plus the newer field of Immersive Healthcare. We're bringing on top talent throughout every area of our company, and we keep delivering in our everyday operations. Those 3 factors have shaped our achievements for a long stretch of time. Lastly, I'd like to recognize and thank the entire Penumbra team for contributing so greatly and collaborating so effectively to design, produce, and supply all of our offerings to doctors and patients, even during these tough times. Thanks for joining us on today's call, and now we'd like to take your questions. Operator, please begin.
Larry Biegelsen
analystLet me begin with the guidance. Clearly, you posted a really strong quarter relative to how you've historically performed seasonally; however, at the midpoint, the Q4 outlook suggests less sequential growth than what we normally get from you folks, and it works out to just about 12% growth year-over-year. So what's behind that cautiousness? And how should we frame that when thinking about 2022? The Street has roughly 17% year-over-year growth baked in. Also, I'd like to verify that your confidence in the $1 billion for 2023 still holds, and I have a follow-up.
Adam Elsesser
executiveLarry, great question. I'll address the final question first, then hand it to Jason for some of the details. The answer is our confidence regarding the 2023 remark about $1 billion is absolutely there; and I believe when you consider our performance this quarter and the guidance ahead, that gets you there fairly fast. So our confidence is high. Today's commentary, I think, reflects that. I'll have Jason cover the specific guidance. But without a doubt, we're very confident about what lies ahead.
Jason Mills
executiveRight, and before we move past that $1 billion point, let me tack on something to what Adam mentioned. You may remember, Larry, that when we made that statement, we actually phrased it as $1 billion plus. And just as a reminder, that "plus" was tied specifically to our Immersive Healthcare business. That's still how we view that statement right now. So — and I do appreciate your question on guidance. Clearly, the sequential improvement in our business during the third quarter was very strong. It was a solid showing, as we discussed, across both Neuro and Vascular. Clearly, stronger on a sequential basis than many others, and clearly a reflection of how strong our products are in our business. So we're mindful of that strong record growth, and we're also mindful of the world and what people are saying regarding COVID. As we noted in our remarks, we saw fairly good growth throughout the quarter, and we anticipate that carrying into the fourth quarter, which is why we expect sequential growth to keep going.
Larry Biegelsen
analystOkay, and for my second question. Adam, regarding the CHEETAH data, what do you expect physicians will zero in on? What is your strategy for using that data? And Adam, we heard nothing at all about Lightning. Does that remain on schedule?
Adam Elsesser
executiveYeah. To begin with, I believe we — I covered quite a bit regarding Lightning. I think you were referring to Thunderbolt.
Larry Biegelsen
analystYeah, Thunderbolt. My apologies, my apologies. That's correct.
Adam Elsesser
executiveAssuming I've got that right — I realize how similar those two names are. Let's begin with CHEETAH, which is only 2 days off. You know, since — I want to show a lot of respect for the doctors who will be presenting the data, and for the proper rules governing that. Obviously — I'll be present there, and I'm eager to discuss it with anybody once the presentation wraps up, and we can get into that in a couple of days; but it goes without saying, there's a great deal of data to work through, and we're looking forward to doing so. When it comes to Thunderbolt, I believe you all know me well enough to recall that last time I brought the name up in a sort of public way. Our preference is to let what we do and what we make speak for themselves; so this quarter it felt like the right call to stop carrying on that discussion, but there is nothing, and I truly mean nothing, in the fact that I didn't say the name that ought to be taken as negative by anyone; and I believe you all can read the fact that I left it out of the public comments in exactly the way I intended it.
Bill Plovanic
analystIt's John here, filling in for Bill this evening. Adam, if you could return to CHEETAH for a moment, would you mind discussing the broader opportunity within coronary? After that, how do you plan to juggle that against your efforts in arterial DVT and PE? And maybe you could also address the overlap in call points? Are there any synergies worth noting there?
Adam Elsesser
executiveAbsolutely. The way we've described that market — and I brought this up during the prepared remarks on today's call — is that we're truly targeting patients carrying an extremely heavy clot burden, or thrombus burden, the ones who need help the most. That's precisely what the CHEETAH trial was built to examine; that's what we'll be reporting out. And that genuinely represents the opportunity. It's a sizable opportunity. Our penetration stands at only about 10%. And as we've noted before, for U.S. patients in coronary, that opportunity is approximately equal in size to the U.S. stroke opportunity. So it's far from trivial. And I believe you're all aware that the major technological shift involves the concept of employing continuous power aspiration rather than certain older technologies. And if you examine some of those earlier studies, they truly underscored how much those studies needed technological innovation to handle patients with high thrombus. So that's the context through which you can view and absorb the data on Friday morning in Orlando. Regarding the call point, clearly, that call point is interventional cardiology. I think every interventional cardiologist handles a substantial number. Occasionally, estimates suggest as much as around 25% of the peripheral work. So there's plainly an obvious synergy between those 2 products, and really it's not — neither one detracts from the other. In reality, they operate extremely, extremely synergistically, and the teams have been concentrating on that for some time.
Analyst
analystWe're eager to see those results. Then, as another question, regarding neuro: once you hit that COVID slowdown, what's your thinking on the willingness to work with lawmakers once more, and on first responders bringing stroke victims to the proper treatment location?
Adam Elsesser
executiveYeah. I'm very happy that you brought that up. For the first time in 2 years, because of the pandemic, I sense and observe what I suppose are a few initial indications that reengagement is beginning. I've devoted a fair amount of time to conversations with our doctors in the field. They're beginning, in the very earliest stages, to possess the capacity, the hours, and the means to head into their nearby communities and begin the sort of regional efforts they used to undertake previously. Yet this quarter we likewise witnessed one more state pass, the state law you mentioned, and that was North Carolina. Consequently, I feel quite hopeful that as we enter this subsequent stage of the pandemic, a bit more momentum is emerging; and as my prepared remarks conveyed, our Neuro team is deeply involved. The energy and momentum are enormous. You witnessed that in the sequential growth within the U.S., and it's a truly, truly thrilling moment to advance the technology. Simultaneously, we are emerging from a genuinely tough 2 years.
Robbie Marcus
analystNice work on a strong quarter. Perhaps to kick things off, Adam, you mentioned quite a few new products coming to market, Lightning 7, certain RED items. You brought up China and the uptake happening over there. What's the way for us to frame how that affected sales this quarter and what you anticipate, say, across the coming 6 to 12 months? And include coronary too. You don't disclose individual products or the various sub-line items within those businesses. So how should we think about where the largest incremental dollar growth is showing up?
Adam Elsesser
executiveYeah. No, that's a really good question. Well, clearly we do separate Neuro from Vascular. So the gain from the RED series in upcoming products, hopefully, across the next 6 months to a year, should be fairly evident, within our Neuro segment. When it comes to the Vascular segment, it's — and I mentioned this during my prepared remarks, everything is clicking. We experienced genuinely strong expansion, on PE and venous and arterial plus coronary; so we're fortunate. We can genuinely make a positive difference for patients across all 4 of those areas. I believe it would be — there's no need to single out one as bigger since every one of them is performing well right now. And that's, I believe, among the truly massive opportunities as the field begins to genuinely absorb and embrace the notion of single-session treatment. It's not merely something people contemplated in a philosophical way anymore. It's now far more embedded in how physicians see things because — partly due to the pandemic and the pressure to open up ICU beds, they're achieving results, especially with the Lightning series in PE, venous and arterial and then getting familiar with CAT RX in their routine practice. And regarding CHEETAH, I think, we'll see, but I believe that can keep going quite dramatically; so it's tough to parse it in a manner that says which one adds more since the entire team is concentrated on every one of them, and every one of them counts. And every one of them is adding value and that provides us, I think, the assurance you can detect in our tone that plenty of growth lies ahead.
Jason Mills
executiveAnd Robbie, to build on that point a bit and return to a few items from our prepared remarks. Clearly, when people examine our Lightning 7 and Lightning 12 offerings, those largely address arterial and venous in transfer. And we did mention sequential double-digit expansion for each. Clearly, we — during this quarter, we're lapping the year ago period, which represented almost a complete quarter of the initial Lightning 12 launch. A few additional items to highlight and recall, we noted the U.S. stroke business rose 17% on a sequential basis. That's clearly driven by how receptive the market has been to the RED series of catheters, and in the United States overall, peripheral thrombectomy grew 10%, spanning all 4 of those areas we referenced, arterial, PE, venous and coronary.
Robbie Marcus
analystThanks. I’ve got a quick follow-up. It’s been some time since we received—you previously provided figures regarding the number of procedures you believed were taking place in the neurothrombectomy markets within and beyond the United States. Do you have any idea where the U.S. and Europe might be headed in terms of procedure volumes this year? And if there’s any method to assess how business performance in those markets has been since last year’s recall, that would be extremely useful.
Adam Elsesser
executiveYes. Handing out exact figures doesn't seem right to me, since tracking them gets somewhat trickier at this stage; down the road, we'll definitely make our best effort to provide that. Still, putting numbers out there while lacking that level of certainty is somewhat tough. As you're aware, the field now includes far more competitors, and all of that adds a bit of difficulty. Let me restate my earlier point: I genuinely believe the past — nearly two years, though not quite a year and a half — has been comparatively — at first, it clearly dropped sharply right when the pandemic hit, and then it kind of came back. What I'm seeing right now — and I should stress this is only anecdotal, so I don't want to sound more confident than the evidence supports. Even so, there's a sense of optimism I'm picking up about patient volumes increasing, and that really began around a month or two back. North Carolina strikes me as a solid illustration of the enthusiasm that continues to exist for carrying out this work and bringing in those patients, so it's a fair question. We'll make an effort to provide you with more concrete details. Still, I'd rather not simply toss out figures. Accuracy matters as much as possible to us.
Robbie Marcus
analystAlright. Let me try to fit in one more quick question. China — I understand it was entirely, or at least mostly, a Medtronic market. Do you have any sense of what kind of impact you're having there? Is it still genuinely early days? Or how should we think about the impact that you're seeing?
Adam Elsesser
executiveYes. I mean, look, China is a big market, and putting a number on the impact to their business is difficult, since that's hard to determine from where we sit. What I can say, based on the conversations I've had, is that there's a tremendous amount of interest in shifting that market toward aspiration-based technology. The physicians in that country have been aware of it for some time. They're eager to obtain the products capable of performing that work. ACE68 is the product launched most recently, and we're witnessing genuine success in those cases. So I think, once again, very early days, meaningful opportunity. And as we've mentioned before, the technology we're using there is slightly older than what we have here; so when you consider that, between now and the future when we can keep bringing the most current things, I'm quite confident that we'll keep doing very well in the China market as we move forward.
Bob Hopkins
analystHey guys and Maggie, I was hoping we might break down Q3 a bit further. You — perhaps I'll pose 2 questions regarding the third quarter. You mentioned that growth sped up as the quarter progressed. I was just curious whether you could give a bit more detail on that, specifically how noticeable it was. Then second, regarding Q3. I was wondering if you might address the effect of COVID, since in certain ways, it's a clear — I mean, clearly, it's a negative owing to hospital disruptions; yet the character of COVID is that it's prothrombotic. Thus there's potentially also an upside for your business, and one of your rivals highlights that each quarter. So I'm just curious if you could offer a bit more detail on Q3 concerning those 2 subjects, the acceleration as the quarter went on and then how COVID affected your figures from those headwind and tailwind angles.
Adam Elsesser
executiveYes. truly, truly excellent question. Let me try to tackle it as well as we can without merely speculating. So our — the first part regarding the quarter, the quarter appeared unexpectedly typical in its progression for a third quarter, and that's what we were attempting to convey. Most quarters do speed up as they proceed, especially in the third quarter when you begin in July. And this seemed fairly typical. And that's what we aimed to highlight. We knew COVID was present; we observed spikes particularly in certain areas a bit later in the quarter, but it had no effect on us; now why is that so? Was it patients who wouldn't have otherwise developed thrombus, but did because they contracted COVID? We've had some anecdotal discussions with individuals about that. And we don't believe that accounted for the majority of — or even a meaningful portion of the growth. We believe we're truly beyond that. Most of those patients are receiving treatment sooner. So they aren't presenting with the type of thrombus that requires mechanical removal. And much of it is genuinely just new physicians being introduced to the technology over time thinking it's time to switch either from another device they're using or from tPA and they're discovering the advantage of the Lightning both, again, on the arterial side and in PE and especially in venous as well. So I think it was genuinely just the usual growth of a truly, truly vital product that does truly, truly excellent work for patients; and that's what gives us considerable confidence that we'll see this persist for some time.
Bob Hopkins
analystAll right, that's excellent. Then I have a single brief follow-up regarding what you said about a 10% sequential increase in vascular thrombectomy. I realize every one of those pieces appears to be performing very nicely — PE, venous, arterial, and coronary. However, how wide is the band surrounding that 10% sequential figure? In other words, among those 4, is 1 expanding at 20% or 30% while others sit in low single digits? Or do they cluster more tightly near 10%? I simply wanted a feel for how much variation exists across the 4 franchises.
Adam Elsesser
executiveRight. In truth, only 3 exist, since determining with any precision whether Lightning is deployed in PE versus venous within Lightning 12 cases is difficult, even though our impression is that both are going well; yet I cannot state with certainty what the split is, given that it's one and the same product. What I can say, though, is that each of them is performing well. I believe we singled out Lightning by name — it's newer. Additional effort remains. So relative to that plus CAT RX, Lightning performed especially strongly. Once more, we'll resume this discussion following Friday, moving ahead. Still, it's a favorable position when everything is adding to our growth at present.
Jason Mills
executiveCorrect, Bob. To restate a point I made previously, that figure of 10% was sequential growth within the United States — I want to be sure that came through clearly. That's one thing. Beyond that, we separately highlighted double-digit expansion for the Lightning 7 franchise and the Lightning 12 franchise, each on its own. And as Adam noted, distinguishing DVT from PE in that context is genuinely difficult. Then, adding briefly to your opening question, you raised the paradigm of whether something is prothrombotic or not. Our response would be to direct you toward another paradigm altogether — namely, that single-session therapy keeps gaining traction. Naturally, tied to that is the fact that with single-session therapy, you aren't consuming intensive care unit resources the way you otherwise would. That paradigm is something we observe, and it likely persists.
Brandon Vazquez
analystThis is Brandon calling in for Margaret. First off, I just wanted to keep the focus on Neuro, where it was a really strong quarter, particularly in the U.S. on the stroke side; and I realize you may not have specific figures for market share. But would it be fair to describe 17% sequential growth as perhaps above the market? And what I'm really trying to ask is, following a stretch that maybe involved some disruptions and a bit of a recall, do you sort of feel that with the RED series of catheters here, you're now on the offensive and gaining share as you go into next year?
Adam Elsesser
executiveYes, absolutely.
Brandon Vazquez
analystThat's clear, no problem.
Adam Elsesser
executiveI could fill in some additional detail. For sure — we couldn't be happier about this. Without a doubt, our current position is excellent. The RED series is performing incredibly strongly, and honestly there aren't enough hours available for us to roll it out at the pace we'd like; even so, this isn't a complete quarter yet, and plenty of positive results are already showing up. So yeah, it truly is — it lifts your spirits; it's thrilling. Spirits are up, and the response from physicians has been genuinely favorable.
Brandon Vazquez
analystUnderstood.
Adam Elsesser
executiveIt's correct that a 17% expansion probably didn't happen in the market.
Brandon Vazquez
analystAll right, and Adam, perhaps more generally speaking, you mentioned possibly bigger spending or an emphasis on efforts around market development. Within Vascular, that could be particularly key since the market is so big and there may be additional opportunity for you to pursue. I'm just wondering whether you might describe the types of market development work you all are putting money into — moving from 10% to 20% penetration and past that might call for some of that; so what are those things you're funding? And how significant are they to growth over perhaps the coming 12 months?
Adam Elsesser
executiveYeah, that's a terrific question. So there is — once more, much like stroke, where we devote time to communities and the hospital systems performing outreach to ensure patients were arriving at the proper place. In this case, the outreach looks somewhat different; yet with people and physicians who have faith in single session and wish to keep that going, there is local outreach to ensure referral patterns are established and that patients are able to see the physicians who are already, in a sense, dedicated to treating them in a single session; so there is certainly work to be done in what we are undertaking and doing to accomplish that. The other space, naturally, is clinical work. We're conducting some studies at this moment. But what's really important is the studies we're beginning to genuinely consider and shape, especially in specific areas such as PE. You can consider truly pursuing all of the remaining patients who aren't even receiving tPA, but are only receiving medical management, and how one would connect those. We've discussed that previously, but we've always wanted to make certain and learn far more. And I believe as we go on here, we're coming to understand increasingly the advantages of the product and technology and beginning those conversations; so once again, plenty ahead, a pretty thrilling moment to deliver this technology to more and more people.
Brandon Vazquez
analystUnderstood; and let me squeeze in one final question, if that's alright. Those new international team members caught my attention, obviously, since that's somewhere you're putting money. Does this perhaps hint at any fresh approaches? Have you gotten to a point where the way you tackle those markets needs some adjustment? And what might that imply for growth abroad during 2022?
Adam Elsesser
executiveRight. Listen, we as an organization have consistently aimed to keep bringing aboard the strongest talent available — individuals who possess knowledge beyond our own and carry deep know-how in fields we can keep gaining from. Those 2 hires overseas, Fred and Joan, fit that description precisely: 2 genuinely remarkable individuals who deliver an enormous amount of experience and reinforce, through what they've done, the things we understand less thoroughly. So indeed, my expectation is that growth outside the US will keep coming over the years to come, and having them here is thrilling. They strengthen our team wonderfully.
David Rescott
analystTo start, I suppose this is a follow-up going back to the Venous segment. We've observed a certain amount of M&A activity in this area involving a few of the bigger diversified medtech players across the last couple of months or so. So how are you viewing the way competition is taking shape here? In other words, do you believe there's an edge for certain thrombectomy offerings by sitting inside a portfolio together with other complementary items aimed at the vascular space? I'd simply like to hear how you're approaching your positioning as competition heats up down the road.
Adam Elsesser
executiveYes. Look, it has made me genuinely, genuinely pleased to watch, in particular, a number of the large corporations recognize that clearing clot from the body using a mechanical thrombectomy device minus tPA and similar things represents the proper path. That's an enormous kind of declaration to the entire field that we're headed in the correct direction, and I believe folks are beginning to genuinely take note of this as what lies ahead. So I think all of it is tremendously significant and not surprising that this would occur. And the timing of it occurring right now, I think, is ideal. When it comes to the technology as such, we hold considerable confidence in our kind of computer-aided Lightning thrombectomy system. It performs genuinely, genuinely well. We're quite familiar with the competing technologies. And just as we are, we're sitting in a really strong position. Yet we also, as you're aware, never remain static; and once you factor in the innovation arriving in this area, which we're developing, we hold considerable confidence that while the market keeps shifting away from tPA drip toward thrombectomy, we'll be positioned exactly where we wish to be in order to catch a large share of those patients and deliver genuinely, genuinely strong outcomes for them.
David Rescott
analystOkay, that's useful. I want to build on a few of the points you made regarding how the peripheral thrombectomy market is developing. It looks like certain rivals, particularly in the pulmonary embolism space, have come out with some head-to-head RCT trials. From what I recall, you've said something before, or at least shown a degree of interest, about running head-to-head studies of that kind in the Venous segment. So what's the thinking there, or what's the broader rationale for either pursuing or not pursuing head-to-head data? And if you don't have that data, or if you choose not to put money into that area, how do you weigh the trade-off between expanding the market versus taking share within it?
Adam Elsesser
executiveYes. No, that's a genuinely excellent question, and I'm happy you raised it. I touched on this in my prior response, but let me try to be clearer. PE, which is what you're referring to, is currently the smallest patient segment in the U.S. — speaking of U.S. figures — where any form of intervention is actually used, with tPA being the majority approach, administered as a drip over some period of time; and that's only roughly 20,000. That's a meaningful number, yet it's a comparatively small group next to how many patients get intervened on in the venous DVT area and on the arterial side. The genuine opening is to target the far bigger population that receives no intervention at all and is simply put on medical management, even though many of them probably have submassive or massive PEs and might do better being treated sooner instead of letting those cases turn quite acute. So that's the trial that would unlock the field, that would expand the field. The trials underway right now — I'm not passing judgment on them — are essentially share-capture trials. Given how much growth we're seeing and what we believe our product can achieve, that's less compelling to us. So our focus is genuinely on that kind of study. We haven't made an announcement, but as I mentioned, we're gaining enough understanding to begin those conversations with certain physician leaders about what would truly open the market in a bigger way. The randomized trials being run at present really concentrate on that same fairly narrow patient pool.
Joanne Wuensch
analystSo it seems like — there are 2 questions. The first concerns gross margins. It seems like that new manufacturing site you've got is starting to drag on them. How should we think about that, not only for Q4 but also going into next year?
Maggie Yuen
executiveYes, Joanne, thank you for asking. Regarding how our Roseville site investment affects our margin, what I'd like to state in my remarks is that these are all deliberate investments. We sped up that investment considerably, entirely because of what we project for our long-term volume growth. So like any investment made in building up a manufacturing site, the effect on near-term margin is going to be somewhat uneven, yet it will keep supporting margin expansion efforts across the year. And I'd also like to mention that, right now, we haven't observed a material impact on our margin from the macro supply chain and inflation side, though we do believe all of this productivity investment will assist us in offsetting a portion of the macro effect over the long term.
Joanne Wuensch
analystAll right. For my follow-up, I want to ask about REAL revenue — that is, money coming in from the REAL system, to put it differently. How should we — it seems like a lot of people already have figures for this in their models. From what I can gather, estimates for next year span from $3 million up to $26 million, and that spread might determine whether you beat consensus or fall short of it. Could you help us wrap our minds around this so we're positioned correctly?
Adam Elsesser
executiveSure; so I don't — we aren't — I'll do my best to tackle that without providing guidance or figures for 2022, since we simply aren't doing that during this call, and I want to make that clear. As for the opportunities in Immersive Healthcare, we believe they are — as you're aware from our Investor Day — truly enormous and substantial; completing the work we described at the Investor Day will take time. That work involves several things. We need to keep developing the platform itself and put in the effort to expand that capacity, so we can host developers and have them working alongside us on content. We also need to put in the effort to create a workable business by establishing a fairly substantial installed base. Every bit of that remains at the very beginning of the effort; so regardless of whether the revenue turns out substantial, we'll provide you with reasonable guidance once we begin discussing our 2022 guidance. But the aim is to lay that out, complete that work, and avoid pursuing short-term revenue next year or while we proceed this way. That matters; even so, there's plenty of excitement on our side because following Investor Day, when there was considerable public attention and we could begin discussing it, we've held many conversations with the health care community — those who would essentially take part, purchasing this, using it with their patients, their residents, and so forth. And I have to say, as I mentioned in my prepared remarks, the interest, the enthusiasm, the desire to have a single company — a trusted company in health care — deliver this in a way where everything is clear, everything is contained, the data is protected, it's a suitable application of this remarkable technology — that degree of interest, honestly, is — I won't claim it shocks me, I knew it existed, but it's genuinely encouraging to witness it emerging after those — that kind of public discussion. So keep watching. We'll try our hardest to give you concrete figures as well as we can down the road; but I believe we're making solid progress here. Thank you.
Jee Hamlyn-Harris
executiveThanks, operator. Our management team and I want to express our appreciation once more for everyone being with us and for the attention you're giving Penumbra. We're eager to share our latest news with you during this fourth quarter call.
Operator
operatorThis concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.